Member Info for moonparty

Bound to be quiet here over Xmas, unlikely to get any news next week.

But lots of news expected in the new year:

- iscib1+ trial news

- further scope trial readouts

- modi1 trial updates

- avidimab/glymab/mab news or deals

Aand there's always the possibility of a new year tip or two.

If they took the money for the extra entitlement it is probably OK and just an admin thing. If they didn't take the money, then they probably screwed up.

If you're quick next week you might be able to buy some at just over 11p on the open market though.

And on the offer side, it seems there are lots of willing buyers paying a small margin over the 11p placing price to soak up the shares!

In my opinion.

Any premium to 11p on the bid will be snapped up by PI's who can buy back at 11p in the OO.

Nothing to see here. Move along please. Come back on the 18th!

£8 a share :)

Thanks Chester, we have till 18 December to make our minds up how many to apply for:

"Latest time and date for acceptance of the Open

Offer and receipt of completed Application Forms

11.00 a.m. on 18 December 2023"

Also, it mentions "The maximum amount to be raised under the Open Offer shall be less than €8 million (or an equivalent amount in pounds sterling)", so it seems possible shareholders will get any excess they apply for, so long as the aggregate total applied for is no more than €8 million.

Douve the £6M is the placing the £8M is including the open offer (£2M), costs are NOT £2M !

The doomies were saying the potential scrapping of IHT would impact AIM (specifically Scancell).

So by that logic, this must be a positive for AIM and specifically Scancell.

Probably down to everybody busy working on the £Billion deal they are about to announce, and they are under instruction to say nothing!

I'm using chapgpt 4, which is an option on the Bing app.

Tried again, same answer 183p per share

Just a bit of fun though, chargpt is not known for its great accuracy - clearly, because it didn't come back with £8 a share!

Just for fun, I asked chargpt this very question, this is the answer it came up with:

The value of Scancell's IP is not easy to estimate, as it depends on many factors such as the stage of development, the market potential, the competitive landscape, the regulatory environment, and the licensing or partnership deals that the company may enter into. However, some analysts have attempted to provide a valuation based on the company's current pipeline and prospects. For example, a recent report by Equity Development estimated that Scancell's IP could be worth up to £1.5 billion, or 183p per share, based on a risk-adjusted net present value (NPV) analysis

I think two factors:

1. Scancell have already indicated they are focussing on scib1 and modi1, so reducing expense in other areas

2. Trial costs should be reduced as trials are now in progress? (bit of a guess this, but I imagine there were substantial start-up costs)

Researcher1, cash runway is extended since last update and better than expected?

You'll have to try harder than that!

Have topped up. GLA!

Scancell clearly not concerned about finances!

Lindy has stated previously that what the big pharma want is lots of data, in order to get the price she wants.

That's what Scancell are now doing.

They won't wait for trial completion or a nice fat report with all the bells and whistles, not if it is blindingly obvious that the data is good.

Data is imminent...

Don't really understand the jumping analogy, but I think you're saying less people are interested the less proven it is?

Absolutely, but that doesn't mean nobody is interested. It will be the smart ones looking now. The herd will follow on great results. So those who are aware of progress now have a whole risk/reward/cost/opportunity problem to solve.

I suspect it is cost that has put suitors off to date, as LD would reject anything she didn't consider 'enough' before it got it formal offer stage. Before one of the resident pedants jumps on this I know the board have limited hard power to reject an offer, but soft power is what it's about.

"so if big pharma know the game why would they jump in early days?"

Lots of reasons:

1. Value - cheaper to buy early if they believe in the product

2. Competition (FOMO) - get in early and reduce possibility of missing out to another suitor

3. Fit with current portfolio / patent expirations

4. Because someone with some nous understands the science and sees the potential ahead of the curve (which is why I think any sale or collaboration is likely to be with a bio already known to Scancell)

Https://www.bloomberg.com/news/articles/2023-07-10/nine-uk-pension-funds-agree-to-invest-5-of-assets-to-startups

Just for a bit of balance, if pensions will be investing 5% of their funds in smaller growth companies will this have a positive impact on AIM stocks, sp wise?